Small is Powerful: Demonstration of the Impact of Nanoformed Piroxicam in a Controlled Clinical Study

Lakio, Satu; Smith, David J.; Andrade, Goncalo; Sandler, Niklas; Evans, Philip; McDermott, John; Roe, Chris; Hӕggström, Edward

doi:10.1007/s11095-023-03624-8

Cited by 1 publication

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This ensures rapid absorption and the rapid onset of action. In the literature, there are examples of the increased dissolution rate leading to more rapid absorption and improved drug delivery performance compared to standard-reference PRX tablets supported by a clinical study [2].…”

Section: In Vitro Drug Release Studymentioning

confidence: 99%

“…Its oral absorption is considered to be limited by its dissolution rate. PRX has a well-established safety profile because it has been used in marketed products for several decades in a variety of dose forms and administration methods, including oral [2]. When administering PRX compared to other NSAIDs, only low doses (20 mg/day) are necessary to achieve a therapeutic effect.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preparation and Investigation of a Nanosized Piroxicam Containing Orodispersible Lyophilizate

Party,

Sümegi,

Ambrus

2024

Micromachines

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory piroxicam (PRX) is a poorly water-soluble drug that provides relief in different arthritides. Reducing the particle size of PRX increases its bioavailability. For pediatric, geriatric, and dysphagic patients, oral dispersible systems ease administration. Moreover, fast disintegration followed by drug release and absorption through the oral mucosa can induce rapid systemic effects. We aimed to produce an orodispersible lyophilizate (OL) consisting of nanosized PRX. PRX was solved in ethyl acetate and then sonicated into a poloxamer-188 solution to perform spray-ultrasound-assisted solvent diffusion-based nanoprecipitation. The solid form was formulated via freeze drying in blister sockets. Mannitol and sodium alginate were applied as excipients. Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) were used to determine the particle size. The morphology was characterized by scanning electron microscopy (SEM). To establish the crystallinity, X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) were used. A disintegration and in vitro dissolution test were performed. DLS and NTA presented a nanosized PRX diameter. The SEM pictures showed a porous structure. PRX became amorphous according to the XRPD and DSC curves. The disintegration time was less than 1 min and the dissolution profile improved. The final product was an innovative anti-inflammatory drug delivery system.

show abstract

Section: In Vitro Drug Release Studymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%